ALLIANZ
31.3.2023 15:12:30 CEST | Business Wire | Press release
As part of the implementation of its ‘Integrated Commercial’ strategy to better serve the full Commercial segment, Allianz Group today announced the leadership for four of its largest Property and Casualty Commercial insurance markets: Australia, France, Germany and the United Kingdom. In each country, the appointed single Commercial lead will represent the integrated Allianz Commercial business and bring to the market Allianz’s full set of solutions for specialty clients, large corporates, and mid-sized companies, simplifying and enhancing the experience of clients and distribution partners.
“The appointment of the regional leaders in our core Allianz Commercial markets is an important, concrete step toward realizing our new integrated model, which brings together our Mid Corporate and Large Corporate insurance business for the benefit of our clients and distribution partners,” said Chris Townsend, Member of the Allianz SE Board of Management.
Townsend added, “As one face to the market, these leaders will represent the full Allianz offering to companies across the entire commercial spectrum and will drive the effective local delivery of our global capabilities.”
Australia: The Allianz Commercial business in Australia will be led by Phuong Ly as Chief General Manager Allianz Commercial, reporting to Richard Feledy, Managing Director of Allianz Australia in conjunction with Joachim Mueller, CEO of Allianz Global Corporate & Specialty (AGCS). For more information, please click here.
France: The Allianz Commercial business in France will be led by Patrick Thiels as Country Managing Director for Allianz Commercial with Frédéric Baccelli as Deputy Country Managing Director for Allianz Commercial. Thiels will report to AGCS CEO Joachim Mueller and to Fabien Wathlé, CEO of Allianz France. For more information, please click here.
Germany: The Allianz Commercial business in Germany will be led by Hans-Joerg Mauthe as Commercial Managing Director, reporting to AGCS Chief Regions and Markets Officer Henning Haagen and to Ulrich Stephan, Board Member of Allianz Versicherungs-AG. For more information, please click here.
United Kingdom: The Allianz Commercial business in the United Kingdom will be led by Nadia Côté as Commercial Managing Director, subject to regulatory approval. She is reporting to AGCS CEO Joachim Mueller and to Colm Holmes, CEO Allianz Holdings UK. For more information, click here.
The appointment of additional Allianz Commercial regional leaders in other markets globally will follow in due course.
Allianz previously announced on March 10, 2023 that it will serve the global commercial insurance segment as one go-to-market business, using the new trading name of Allianz Commercial, combining its AGCS business serving large corporate and specialty clients together with the insurance businesses of Allianz’s operating entities serving mid-sized country-based accounts. Joachim Mueller will lead Allianz Commercial as part of his responsibilities as CEO of AGCS SE.
About Allianz
The Allianz Group is one of the world's leading insurers and asset managers with more than 122 million* private and corporate customers in more than 70 countries. Allianz customers benefit from a broad range of personal and corporate insurance services, ranging from property, life and health insurance to assistance services to credit insurance and global business insurance. Allianz is one of the world’s largest investors, managing around 683 billion euros** on behalf of its insurance customers. Furthermore, our asset managers PIMCO and Allianz Global Investors manage about 1.6 trillion euros of third-party assets. Thanks to our systematic integration of ecological and social criteria in our business processes and investment decisions, we are among the leaders in the insurance industry in the Dow Jones Sustainability Index. In 2022, over 159,000 employees achieved total revenues of 152.7 billion euros and an operating profit of 14.2 billion euros for the group.
These assessments are, as always, subject to the disclaimer provided below.
* Including non-consolidated entities with Allianz customers.
** As of Dec 31, 2022
Cautionary note regarding forward-looking statements
This document includes forward-looking statements, such as prospects or expectations, that are based on management's current views and assumptions and subject to known and unknown risks and uncertainties. Actual results, performance figures, or events may differ significantly from those expressed or implied in such forward-looking statements.
Deviations may arise due to changes in factors including, but not limited to, the following: (i) the general economic and competitive situation in the Allianz’s core business and core markets, (ii) the performance of financial markets (in particular market volatility, liquidity, and credit events), (iii) adverse publicity, regulatory actions or litigation with respect to the Allianz Group, other well-known companies and the financial services industry generally, (iv) the frequency and severity of insured loss events, including those resulting from natural catastrophes, and the development of loss expenses, (v) mortality and morbidity levels and trends, (vi) persistency levels, (vii) the extent of credit defaults, (viii) interest rate levels, (ix) currency exchange rates, most notably the EUR/USD exchange rate, (x) changes in laws and regulations, including tax regulations, (xi) the impact of acquisitions including and related integration issues and reorganization measures, and (xii) the general competitive conditions that, in each individual case, apply at a local, regional, national, and/or global level. Many of these changes can be exacerbated by terrorist activities.
No duty to update
Allianz assumes no obligation to update any information or forward-looking statement contained herein, save for any information we are required to disclose by law.
Privacy Note
Allianz SE is committed to protecting your personal data. Find out more in our privacy statement.
Chairman of the Supervisory Board: Michael Diekmann.
Board of Management: Oliver Bäte, Chairman. Dr. Sirma Boshnakova, Dr. Barbara Karuth-Zelle, Dr. Klaus-Peter Röhler, Giulio Terzariol, Dr. Günther Thallinger, Christopher Townsend, Renate Wagner, Dr. Andreas Wimmer
(Release / Stand 01.2023). For VAT-Purposes: VAT-Registration Number: DE 129 274 114; Insurance services are exempt from VAT. Allianz SE, Munich, Comm.Reg.: Munich HRB 164232
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005262/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Qualcomm Announces Quarterly Cash Dividend17.4.2026 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.92 per common share, payable on June 25, 2026, to stockholders of record at the close of business on June 4, 2026. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing business
Byondis to Present Data from its Novel ADC Technology Platforms at the American Society for Cancer Research Meeting 202617.4.2026 13:00:00 CEST | Press release
Byondis B.V., an independent biopharmaceutical company creating innovative targeted medicines for patients with cancer, will profile the Company’s first-in-class antifolate and phosphonate antibody-drug conjugate (ADC) technology platforms in poster sessions at the American Society for Cancer Research (AACR) Annual Meeting 2026 in San Diego, CA, from today through to 22 April. Wim Dokter, PhD, Chief Scientific Officer at Byondis, said: “The research we are presenting at AACR highlights the potential of two of our state-of-the-art ADC technology platforms to address significant limitations with current therapeutic approaches in cancer treatment. Our first-in-class antifolate linker-drug platform features an orthogonal mechanism of action based on clinically validated biology. This approach is engineered to address acquired resistance that can develop with current ADC treatments, positioning it for use across treatment lines. Our phosphonate linker-drug platform offers a complementary me
BlackBerry, JVCKENWOOD and SK Telecom Join Sisvel POS Patent Pool as Licensors17.4.2026 09:04:00 CEST | Press release
The new Sisvel Point of Sale (POS) patent pool, announced on 1 April, has added three new licensors in the last two weeks. BlackBerry, JVCKENWOOD and SK Telecom have joined founding licensors Huawei, LG Electronics and Nokia in making their patents available for license through the programme. Sisvel POS covers 2G, 3G, 4G and 5G technologies. It is the first joint licensing programme to address point of sale devices – a category of product that has leveraged cellular connectivity to transform customer payment processing. Participating patent owners make their relevant standards essential patents (SEPs) available on FRAND terms, simplifying access to essential IP rights for POS device makers. Early participation incentives for licensors are available until mid-May. Parties interested in joining the pool are encouraged to contact Sisvel as soon as possible. “BlackBerry, JVCKENWOOD and SK Telecom are first-rate cellular innovators. I am pleased they have chosen to become part of Sisvel POS
Adtran wins two FTTH Innovation Awards for AI‑driven network operations and home Wi‑Fi17.4.2026 09:00:00 CEST | Press release
News summary: Mosaic One Clarity recognized for applying explainable AI to shift fiber operations from reactive troubleshooting to proactive assurance Adtran’s SDG 8000 and 9000 Series honored for delivering multigigabit, whole‑property Wi‑Fi with unified software and cloud management Awards highlight Adtran’s focus on innovation that helps service providers scale fiber efficiently while improving customer experience Adtran today announced two wins at the FTTH Innovation Awards 2026, recognizing its leadership across in-home connectivity and AI‑driven network operations. The company received awards in the categories for ‘Active infrastructure – home network’ and ‘Artificial intelligence (AI), machine learning and other software.’ Organized by FTTH Council Europe, the annual awards honor technologies that advance fiber deployment while improving scalability, operational efficiency and user experience. Voted by FTTH Conference 2026 speakers, the results reflect peer recognition for Mosai
Samsung Bioepis Highlights Consistent Efficacy of SB16 (OBODENCE®; Denosumab) Across Osteoporosis Patient Subgroups at WCO-IOF-ESCEO 202617.4.2026 08:00:00 CEST | Press release
- Subgroup analysis from Phase 3 study demonstrates consistent efficacy of SB16 across key patient populations - Results reinforce the totality-of-evidence supporting SB16 biosimilarity Samsung Bioepis Co., Ltd. announced today new data supporting consistent efficacy of SB16 (OBODENCE®1), a biosimilar to Prolia2 (denosumab) across patient subgroups compared to the reference denosumab. The data will be presented as a poster presentation at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO) 2026 in Prague from April 16 to 19. “Consistent efficacy across patient subgroups is critical in reinforcing physician confidence and advancing treatment accessibility for patients with osteoporosis,” said Jeehoon Ghil, Vice President and Medical & Lifecycle Safety Team Leader at Samsung Bioepis. “Such data contribute to the robustness of the overall biosimilarity assessment and support the clinical confidence in our denosumab biosimilar.” SB16 was evaluate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
